Found: 72
Select item for more details and to access through your institution.
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2455, doi. 10.1007/s00432-021-03784-3
- By:
- Publication type:
- Article
Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 12, p. 1736, doi. 10.1093/jjco/hyab158
- By:
- Publication type:
- Article
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2020, v. 50, n. 5, p. 617, doi. 10.1093/jjco/hyaa033
- By:
- Publication type:
- Article
Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2018, v. 48, n. 9, p. 822, doi. 10.1093/jjco/hyy107
- By:
- Publication type:
- Article
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
- Published in:
- Japanese Journal of Clinical Oncology, 2017, v. 47, n. 9, p. 840, doi. 10.1093/jjco/hyx084
- By:
- Publication type:
- Article
Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 2, p. 1633, doi. 10.1007/s00520-021-06572-4
- By:
- Publication type:
- Article
Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 7, p. 3961, doi. 10.1007/s00520-020-05953-5
- By:
- Publication type:
- Article
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer.
- Published in:
- Supportive Care in Cancer, 2015, v. 23, n. 6, p. 1699, doi. 10.1007/s00520-014-2534-3
- By:
- Publication type:
- Article
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer.
- Published in:
- Cancer Reports, 2024, v. 7, n. 9, p. 1, doi. 10.1002/cnr2.70004
- By:
- Publication type:
- Article
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-30676-y
- By:
- Publication type:
- Article
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 2, p. 356, doi. 10.1007/s10637-023-01353-8
- By:
- Publication type:
- Article
Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 403, doi. 10.1007/s10637-021-01191-6
- By:
- Publication type:
- Article
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 411, doi. 10.1007/s10637-021-01183-6
- By:
- Publication type:
- Article
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1732, doi. 10.1007/s10637-021-01140-3
- By:
- Publication type:
- Article
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1716, doi. 10.1007/s10637-021-01136-z
- By:
- Publication type:
- Article
Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 2, p. 571, doi. 10.1007/s10637-020-01005-1
- By:
- Publication type:
- Article
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1612, doi. 10.1007/s10637-020-00917-2
- By:
- Publication type:
- Article
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 194, doi. 10.1007/s10637-019-00808-1
- By:
- Publication type:
- Article
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 184, doi. 10.1007/s10637-018-0633-6
- By:
- Publication type:
- Article
The efficacy and safety of anamorelin among patients with diabetes.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 8, p. 1115, doi. 10.1007/s10147-024-02546-8
- By:
- Publication type:
- Article
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 2, p. 96, doi. 10.1007/s10147-023-02451-6
- By:
- Publication type:
- Article
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 659, doi. 10.1007/s10147-020-01856-x
- By:
- Publication type:
- Article
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
- Published in:
- International Journal of Clinical Oncology, 2018, v. 23, n. 6, p. 1052, doi. 10.1007/s10147-018-1305-4
- By:
- Publication type:
- Article
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2017, v. 22, n. 4, p. 690, doi. 10.1007/s10147-017-1118-x
- By:
- Publication type:
- Article
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
- Published in:
- International Journal of Clinical Oncology, 2015, v. 20, n. 4, p. 668, doi. 10.1007/s10147-014-0761-8
- By:
- Publication type:
- Article
Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835920987647
- By:
- Publication type:
- Article
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835920987647
- By:
- Publication type:
- Article
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
- Published in:
- BMC Cancer, 2016, v. 16, p. 1, doi. 10.1186/s12885-016-2902-0
- By:
- Publication type:
- Article
The effects of advanced age and serum α<sub>1</sub>-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 11, p. 2416, doi. 10.1111/bcp.13354
- By:
- Publication type:
- Article
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11417-w
- By:
- Publication type:
- Article
Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 2, p. 1451, doi. 10.1002/cam4.5035
- By:
- Publication type:
- Article
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 21, p. 7503, doi. 10.1002/cam4.4268
- By:
- Publication type:
- Article
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 1, p. 247, doi. 10.1002/cam4.3631
- By:
- Publication type:
- Article
Multiple tuberculous nodules with metachronous changes: a case report.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 6, n. 5, p. 718, doi. 10.3892/mco.2017.1198
- By:
- Publication type:
- Article
Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
- Published in:
- Molecular & Clinical Oncology, 2016, v. 5, n. 5, p. 575, doi. 10.3892/mco.2016.1001
- By:
- Publication type:
- Article
Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 25, p. 1831, doi. 10.1111/1759-7714.15403
- By:
- Publication type:
- Article
Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 21, p. 1665, doi. 10.1111/1759-7714.15382
- By:
- Publication type:
- Article
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 6, p. 477, doi. 10.1111/1759-7714.15218
- By:
- Publication type:
- Article